A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Completed

• Conditions: Melanoma

• Registration Number: NCT05115006
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-07
• Study First Submitted: 2021-10-28
• Study First Submitted QC: 2021-11-09
• Study First Posted: 2021-11-10
• Status Verified: 2022-06
• Primary Completion: 2022-06-02
• Study Completion: 2022-06-02
• Last Update Submitted: 2022-06-29
• Last Update Posted: 2022-06-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 294

Inclusion Criteria

• Self-reported medical diagnosis of stage II or stage III melanoma
• Have been resected (had surgery) for their melanoma within 12 months prior to study participation

Exclusion Criteria

• Self-reported stage IIa
• Self-reported recurrence of melanoma after surgery

Other protocol-defined inclusion/exclusion criteria apply

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Preference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks	At Baseline

Trial Locations

Locations (1)

Local Institution; 🇦🇺 Melbourne, Victoria, Australia